Ventricular Dysplasia

Ventricular dysplasia is a heart-muscle disease in which parts of the ventricle (often the right ventricle, sometimes the left, or both) are replaced over time by scar and fat-like tissue. This damaged muscle is “irritable,” so it can trigger dangerous heart rhythms (ventricular tachycardia or fibrillation) and, in some people, heart failure. Doctors now group these conditions under the broader name arrhythmogenic cardiomyopathy (ACM), which includes classic ARVC (right-sided), ALVC (left-sided), and biventricular disease. Heart Rhythm Journal+1

You may also hear names like arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D), arrhythmogenic left ventricular cardiomyopathy (ALVC), arrhythmogenic cardiomyopathy (ACM), or simply arrhythmogenic ventricular dysplasia. Across these labels, the core problem is the same: fibrous and fatty replacement of heart muscle that increases the risk of ventricular arrhythmias and sudden cardiac death. PubMed+1

“Ventricular dysplasia” most often refers to arrhythmogenic cardiomyopathy (ACM) and especially its classic form, arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D). In this disease, parts of the heart muscle—usually the right ventricle, sometimes the left or both—are gradually replaced by scar and fatty tissue. That abnormal tissue makes the heart irritable, so fast, dangerous heart rhythms (ventricular tachycardia or fibrillation) can start. Over time, the pumping function can also weaken and cause heart-failure symptoms. ARVC is usually genetic (runs in families) and linked to tiny “spot-weld” structures (desmosomes) that hold heart cells together. With exercise and mechanical stress, weak cell-to-cell connections break down, causing injury, inflammation, and scarring. That is why ARVC is a well-known cause of sudden cardiac death in young people and athletes. ScienceDirect+3PMC+3PMC+3

Other names

Doctors and papers use several names that point to the same disease family:

• Arrhythmogenic right ventricular cardiomyopathy (ARVC) / Arrhythmogenic right ventricular dysplasia (ARVD) — the classic, right-ventricle-dominant form. PubMed

• Arrhythmogenic cardiomyopathy (ACM) — umbrella term that includes right-dominant, left-dominant (ALVC), and biventricular forms. These forms are brought together in modern diagnostic systems (e.g., the 2020 Padua criteria and subsequent European Task Force/ESC guidance). PMC+2PMC+2

---

Types

1) Right-dominant ARVC
The scar–fat replacement is mainly in the right ventricle (often in “triangle of dysplasia” zones). Rhythm problems commonly show a left-bundle-branch-block pattern on ECG during ventricular tachycardia because the arrhythmia starts in the right ventricle. PMC

2) Left-dominant arrhythmogenic cardiomyopathy (ALVC)
The left ventricle is mainly involved. Cardiac MRI typically shows scarring (late gadolinium enhancement) in the outer wall, and genetics often point to desmoplakin or other non-PKP2 genes. Ventricular tachycardia may have a right-bundle-branch-block pattern. AHA Journals+1

3) Biventricular ACM
Both ventricles show disease. People can have features of ARVC and dilated cardiomyopathy together, so MRI and a structured, criteria-based approach are important. International Journal of Cardiology+1

---

Causes and contributors

In most people, more than one factor interacts: a genetic tendency plus mechanical stress (like intense endurance exercise) and sometimes inflammation. PMC+1

1. PKP2 (plakophilin-2) gene variants
   This is the most common gene defect in ARVC. It weakens the “rivets” that connect heart muscle cells. Oxford Academic

2. DSP (desmoplakin) variants
   Often linked to left-dominant or biventricular disease with scarring on MRI. Can also involve skin/hair (cardio-cutaneous syndromes). AHA Journals

3. DSG2 (desmoglein-2) variants
   A core desmosomal gene; many families with ARVC carry DSG2 changes. AHA Journals

4. DSC2 (desmocollin-2) variants
   Another desmosomal “glue” protein; changes destabilize cell adhesion. PMC

5. JUP (plakoglobin) variants
   Historically key in proving ARVC is a “desmosome disease.” PMC

6. TMEM43 variants
   Especially TMEM43 p.S358L in certain populations; associated with severe disease. PMC

7. PLN (phospholamban) variants
   A calcium-handling gene; can show arrhythmias with dilated or arrhythmogenic features. Oxford Academic

8. DES (desmin) variants
   A cytoskeletal gene that can mimic or overlap ACM with myopathy features. Oxford Academic

9. LMNA variants
   Nuclear-envelope gene; causes arrhythmias and cardiomyopathy with early conduction disease. Oxford Academic

10. TGFB3 and other rare genes
    Less common but reported; they modify scar pathways. PMC

11. High-intensity endurance exercise
    Endurance sports put repeated stretch on the right ventricle; in genetically predisposed people this speeds up disease and raises rhythm risk. AHA Journals

12. Recurrent myocarditis-like episodes
    “Hot-phase” flares with chest pain and troponin rise may precede or accompany ACM, leading to scar. International Journal of Cardiology

13. Inflammation and immune triggers
    Inflammation around desmosomal injury promotes fibro-fatty replacement. PMC

14. Male sex / hormones
    Men often show earlier or more severe disease—possibly due to hormonal and exercise exposures. AHA Journals

15. Family history of ARVC/ACM or sudden death
    Inherited patterns are common; relatives may be silent carriers who need screening. Oxford Academic

16. Frequent ectopic beats / sustained VT
    Arrhythmias themselves can worsen function (tachycardia-induced cardiomyopathy) in a vicious cycle. Oxford Academic

17. Pregnancy-related hemodynamic stress (in some)
    Extra volume load can unmask disease in predisposed individuals; management is guideline-directed. PubMed

18. Alcohol or stimulant misuse (as cofactors)
    These can provoke arrhythmias and stress diseased myocardium. PubMed

19. Aging and cumulative mechanical stress
    Longer exposure means more microscopic injury and repair. PMC

20. Unknown / gene-negative ACM
    A sizable minority have no identified mutation but fit clinical criteria. Diagnosis rests on imaging, ECG, arrhythmias, and family evaluation. Oxford Academic

---

Common symptoms

1. Palpitations
   Skipped or racing beats happen because scar and fat create “short-circuits” that fire off ventricular tachycardia. PMC

2. Lightheadedness or near-fainting
   Fast rhythms lower blood pressure and reduce brain blood flow. AHA Journals

3. Fainting (syncope)
   Sudden loss of consciousness can be the first sign and signals higher risk. AHA Journals

4. Chest fluttering during exercise
   Exertion often triggers arrhythmias in ARVC because the right ventricle is stressed. AHA Journals

5. Chest discomfort
   In “hot phases,” people can feel chest pain similar to myocarditis. International Journal of Cardiology

6. Shortness of breath with activity
   If pumping weakens, pressure rises in the heart and lungs. PMC

7. Fatigue and reduced exercise capacity
   Less effective pumping and frequent arrhythmias sap energy. PMC

8. Swelling of ankles or abdomen
   Right-sided heart failure causes fluid buildup. PMC

9. Irregular pulse noticed on home devices
   Wearables can pick up frequent ventricular ectopy. (Confirm with medical-grade tests.) PubMed

10. Nocturnal shortness of breath
    Fluid shifts when lying flat can reveal ventricular dysfunction. PubMed

11. Panic-like feelings during tachycardia
    Adrenaline surges with awareness of rapid heartbeats. AHA Journals

12. Worsening symptoms during illness or dehydration
    Physiologic stress can provoke arrhythmias. PubMed

13. Episodes of sudden cardiac arrest (some patients)
    The most serious presentation; urgent defibrillation is lifesaving. ScienceDirect

14. Family members with similar symptoms
    Because ARVC is often inherited, patterns run in families. Oxford Academic

15. Sometimes no symptoms at all
    Silent disease can be discovered on screening, imaging, or ECG. PubMed

---

Diagnostic tests

Modern diagnosis uses structured criteria that add up evidence from ECG, arrhythmia monitoring, imaging, family/genetics, and (rarely) biopsy. The widely used references are the 2010 Revised Task Force Criteria and the 2020 Padua/International criteria (updated frameworks for right-, left-, and biventricular disease). PubMed+2PMC+2

A) Physical-exam based (bedside) assessments

1. Vital signs and oxygen saturation
   Doctors check heart rate, blood pressure, and oxygen. Persistently fast or irregular pulses or low blood pressure can hint at active arrhythmia or heart-failure physiology. PubMed

2. Jugular venous pressure and peripheral edema
   Neck-vein distention and ankle swelling suggest the right ventricle is failing and backing up fluid. PMC

3. Heart sounds and murmurs
   A gallop or tricuspid-regurgitation murmur can appear when the right ventricle dilates. PMC

4. Precordial palpation
   A right-ventricular heave or diffuse, displaced impulse may reflect enlargement. (Always confirmed with imaging.) PubMed

B) “Manual” or functional tests you actively perform

5. Exercise (treadmill) testing
   Exercise can bring out ventricular arrhythmias that are not seen at rest; it also shows exercise tolerance. Used carefully in ARVC because intense exertion can trigger dangerous rhythms. PubMed

6. Ambulatory rhythm monitoring (Holter/event patch)
   You “wear” a monitor for 1–14+ days. Frequent premature ventricular beats, non-sustained VT, or sustained VT support the diagnosis and guide treatment. Oxford Academic

7. Family screening (cascade testing workflow)
   Not a blood “lab,” but a structured clinic process: ECG, imaging, and sometimes genetics in first-degree relatives—key for an inherited disease. PubMed

C) Laboratory & pathological tests

8. Cardiac biomarkers during “hot phases”
   Troponin can rise during myocarditis-like flares; inflammation then heals with scar and supports an ACM phenotype. International Journal of Cardiology

9. Natriuretic peptides (BNP/NT-proBNP)
   Elevated values suggest stretch and heart failure from ventricular dysfunction. PubMed

10. Comprehensive genetic testing panel
    Looks for pathogenic variants (PKP2, DSP, DSG2, DSC2, JUP, TMEM43, PLN, LMNA, DES, and others). A positive, disease-causing variant increases diagnostic weight and triggers family screening. Pre- and post-test counseling are recommended by guidelines. Oxford Academic

11. Endomyocardial biopsy (select cases)
    Tissue samples from the right ventricle can show fibro-fatty replacement, but sampling error and risk mean it is reserved for difficult cases or to rule out mimics. PubMed

D) Electrodiagnostic tests

12. 12-lead ECG
    Classic findings include T-wave inversion in right precordial leads (V1–V3), epsilon waves, prolonged terminal activation, and ventricular arrhythmias with LBBB morphology. These are part of the formal criteria. PubMed

13. Signal-averaged ECG
    Looks for “late potentials” that reflect slow conduction in scarred tissue. This can support the diagnosis in the criteria sets. PubMed

14. Extended Holter / event monitor (detailed above)
    Quantifies burden of ventricular ectopy and non-sustained VT, which carry diagnostic weight and help with risk assessment. Oxford Academic

15. Electrophysiology study (EPS)
    Catheters map arrhythmia circuits. It may help plan ablation for recurrent VT but is not required to make the diagnosis in most cases. PubMed

E) Imaging tests

16. Transthoracic echocardiogram
    Ultrasound shows right-ventricular dilation, reduced function, and regional wall-motion abnormalities (e.g., RV outflow tract enlargement). These echo signs are included in diagnostic criteria. Medscape

17. Cardiac MRI (CMR) with late gadolinium enhancement (LGE)
    MRI is the cornerstone in modern evaluation. It shows thinning, bulging, and scarring (LGE) in the right, left, or both ventricles. The Padua/International criteria emphasize CMR patterns to classify right-, left-, and biventricular disease. PMC+1

18. Right ventricular angiography (older/selected use)
    Can show aneurysms and regional wall bulges, historically part of ARVC assessment before MRI became widely available. PubMed

19. Cardiac CT
    Occasionally used if MRI is not possible; can show fat and structural abnormalities but exposes you to radiation. PubMed

20. FDG-PET (to look for active inflammation or sarcoid mimic)
    Helpful when the picture is unclear and doctors need to rule in/out inflammatory cardiomyopathy that can look like ACM. PubMed

---

Non-pharmacological treatments (therapies & others)

Below are practical, non-drug strategies. For each, I explain the purpose and the mechanism/how it helps.

1. Genetic counseling and family cascade testing
   Purpose: Identify at-risk relatives early, offer surveillance, and guide lifestyle choices.
   Mechanism: Many ARVC/ACM genes are autosomal dominant; testing first-degree relatives allows ECG/echo/CMR monitoring and early interventions that reduce arrhythmic events. Heart Rhythm Journal

2. Personalized exercise restriction
   Purpose: Reduce arrhythmia risk and slow disease progression.
   Mechanism: Limiting high-intensity/competitive sports lowers adrenergic surges and mechanical stress on a vulnerable ventricle, reducing ventricular ectopy/VT. European Society of Cardiology+1

3. Arrhythmia trigger avoidance (stimulants)
   Purpose: Lower risk of ventricular tachyarrhythmias.
   Mechanism: Avoiding excessive caffeine, energy drinks, recreational stimulants, and sympathomimetic decongestants minimizes catecholamine-driven ectopy in scarred myocardium. (Guidelines broadly caution against adrenergic triggers in cardiomyopathy.) PubMed

4. Electrolyte optimization under medical supervision
   Purpose: Keep potassium and magnesium in the normal range to decrease ectopy.
   Mechanism: Correcting low K/Mg reduces early afterdepolarizations and ventricular irritability; done with labs and clinician guidance. PubMed

5. Syncope safety planning
   Purpose: Prevent injury from fainting episodes.
   Mechanism: Education on early warning signs, safe postures, and when to seek urgent care; integrates with ICD care plans where indicated. PubMed

6. Remote rhythm monitoring (as advised)
   Purpose: Detect arrhythmias early.
   Mechanism: Periodic Holter, event monitors, or implantable loop recorders help pick up silent VT/NSVT and guide therapy escalation. PubMed

7. Cardiac rehabilitation (low-intensity, supervised)
   Purpose: Maintain functional capacity safely.
   Mechanism: Structured, heart-safe activity within prescribed heart-rate limits and symptom checkpoints; avoids high-load endurance work. European Society of Cardiology

8. Psychological support and anxiety management
   Purpose: Reduce stress-related adrenergic surges and improve adherence.
   Mechanism: CBT, mindfulness, and counseling reduce sympathetic drive and help patients cope with ICD anxiety and activity limits. PubMed

9. Lifestyle sleep hygiene
   Purpose: Stabilize autonomic tone and reduce ectopy.
   Mechanism: Sufficient sleep and treating sleep apnea can lower nocturnal arrhythmia burden; sleep apnea treatment improves ventricular arrhythmia control in cardiomyopathy. PubMed

10. Vaccination & infection prevention
    Purpose: Avoid fever/dehydration triggers and myocarditis-like flares.
    Mechanism: Illness can exacerbate arrhythmias; vaccination lowers systemic stressors that may precipitate events in vulnerable hearts. PubMed

11. Alcohol moderation or avoidance
    Purpose: Reduce arrhythmia triggers.
    Mechanism: Alcohol can provoke atrial/ventricular arrhythmias and cardiomyopathy remodeling; moderation reduces ectopy risk. PubMed

12. Heart-healthy nutrition (Mediterranean-style pattern)
    Purpose: Support overall cardiovascular health and comorbid risk factors.
    Mechanism: Emphasizes whole foods, unsaturated fats, and sodium control—helpful for blood pressure and heart failure risk as disease advances. PubMed

13. Medication review for pro-arrhythmic agents
    Purpose: Avoid drugs that worsen arrhythmia risk.
    Mechanism: Periodic review to minimize QT-prolonging or adrenergic medications where possible. PubMed

14. Pregnancy planning (pre-conception counseling)
    Purpose: Plan safe management if pregnancy is desired.
    Mechanism: Reviews medication safety, activity guidance, and monitoring plans for arrhythmias and ventricular function during pregnancy. PubMed

15. Workplace/activity risk assessment
    Purpose: Lower injury risk if syncope/ICD shocks occur.
    Mechanism: Tailors duty restrictions (e.g., heights, heavy machinery) to individual arrhythmic risk. PubMed

16. Emergency action plan training
    Purpose: Improve outcomes if VT/VF happens.
    Mechanism: Family training in CPR/AED use and knowing when to call emergency services. PubMed

17. Sodium/fluid guidance in symptomatic RV dysfunction
    Purpose: Manage congestion if right-sided heart failure emerges.
    Mechanism: Diet and diuretic plans (clinician-directed) can relieve edema and reduce hospitalization. PubMed

18. Smoking cessation
    Purpose: Reduce overall cardiovascular risk and arrhythmic burden.
    Mechanism: Eliminating nicotine lowers sympathetic stimulation and improves vascular and myocardial health. PubMed

19. Regular follow-up in an inherited arrhythmia/cardiomyopathy clinic
    Purpose: Centralize expert care.
    Mechanism: Multidisciplinary teams coordinate imaging, genetics, electrophysiology, and lifestyle guidance for best outcomes. Heart Rhythm Journal

20. Shared decision-making for ICD and ablation
    Purpose: Choose the right time for device or procedure.
    Mechanism: Structured discussions about risks, benefits, and life impact of ICDs/ablation based on guideline criteria and personal values. European Society of Cardiology

---

Drug treatments

Important: Medicine choice and dose must be individualized by your cardiologist/electrophysiologist. The ranges below are typical references from major guidelines; your clinician may choose differently for you. PubMed

1. Metoprolol (beta-blocker; e.g., succinate 25–200 mg once daily)
   Purpose: First-line to blunt adrenaline and reduce ventricular ectopy.
   Mechanism: β1-blockade lowers sympathetic drive, suppressing triggered activity.
   Timing: Daily, titrated to heart-rate/symptoms.
   Side effects: Fatigue, low blood pressure, bradycardia. PubMed

2. Nadolol or Propranolol (non-selective beta-blockers; e.g., nadolol 20–160 mg once daily)
   Purpose: Alternative beta-blockade; sometimes preferred for arrhythmia control.
   Mechanism: β1/β2 blockade decreases adrenergic arrhythmias.
   Side effects: Similar to above; propranolol may affect sleep/mood. PubMed

3. Sotalol (class III + beta-blocker; typical 80–160 mg twice daily)
   Purpose: Suppress VT/NSVT when beta-blocker alone is insufficient.
   Mechanism: Potassium-channel blockade prolongs repolarization; plus beta-blockade.
   Side effects: QT prolongation (torsades risk), bradycardia; needs QT and renal monitoring. PubMed

4. Amiodarone (class III; loading 800–1200 mg/day then 100–200 mg/day)
   Purpose: Potent suppression of recurrent VT/VF or shocks in selected patients.
   Mechanism: Multi-channel blockade and anti-adrenergic effects.
   Side effects: Thyroid, liver, lung, skin, eye toxicity; many drug interactions—use thoughtfully. PubMed

5. Flecainide (class Ic; 50–150 mg twice daily; often with beta-blocker)
   Purpose: Adjunct in selected patients without significant structural LV disease when other options fail (specialist decision).
   Mechanism: Sodium-channel blockade reduces re-entry/triggered activity.
   Side effects: Pro-arrhythmia in structural disease; QRS widening; needs close EP supervision. PubMed

6. Mexiletine (class Ib; 150–200 mg three times daily)
   Purpose: Add-on for refractory ventricular ectopy/VT.
   Mechanism: Sodium-channel blockade shortens action potential in abnormal tissue.
   Side effects: GI upset, tremor, neurologic effects; use with specialist oversight. PubMed

7. Ivabradine (sinus node If inhibitor; 2.5–7.5 mg twice daily)
   Purpose: Lower heart rate when beta-blockers are limited by side effects, potentially reducing adrenergic triggers.
   Mechanism: Slows sinus rate without lowering blood pressure.
   Side effects: Visual phenomena (phosphenes), bradycardia; off-label in ARVC/ACM. PubMed

8. ACE inhibitors (e.g., Enalapril 2.5–20 mg twice daily)
   Purpose: Ventricular remodeling prevention if systolic dysfunction develops.
   Mechanism: RAAS blockade reduces fibrosis and afterload, supporting RV/LV function.
   Side effects: Cough, kidney issues, high potassium. PubMed

9. ARBs (e.g., Valsartan 40–160 mg twice daily)
   Purpose: As above when ACEI not tolerated.
   Mechanism: Angiotensin II receptor blockade.
   Side effects: Dizziness, hyperkalemia; monitor kidney function. PubMed

10. ARNI (Sacubitril/Valsartan; start 24/26–49/51 mg twice daily)
    Purpose: For symptomatic systolic dysfunction meeting heart-failure criteria.
    Mechanism: RAAS + neprilysin modulation improves neurohormonal balance.
    Side effects: Hypotension, hyperkalemia; not a primary antiarrhythmic. PubMed

11. Mineralocorticoid receptor antagonists (e.g., Spironolactone 12.5–25 mg daily)
    Purpose: Add-on for heart-failure phenotype.
    Mechanism: Anti-fibrotic and diuretic effects.
    Side effects: High potassium, kidney function changes, gynecomastia with spironolactone. PubMed

12. Loop diuretics (e.g., Furosemide 20–80 mg as directed)
    Purpose: Symptom relief for fluid overload from RV failure.
    Mechanism: Promotes diuresis, reducing edema and congestion.
    Side effects: Low potassium/magnesium, dehydration; monitor electrolytes. PubMed

13. Anticoagulation (e.g., DOACs such as Apixaban 5 mg twice daily—if indicated)
    Purpose: Prevent clots in atrial fibrillation, ventricular thrombus, or severe chamber dilation per guideline indications.
    Mechanism: Factor inhibition reduces thromboembolism risk.
    Side effects: Bleeding; decision is individualized. PubMed

14. Dapagliflozin/Empagliflozin (SGLT2 inhibitors; standard HF dosing)
    Purpose: In cardiomyopathy with reduced EF meeting HF criteria, these improve outcomes regardless of diabetes.
    Mechanism: Multi-factor metabolic and hemodynamic benefits.
    Side effects: Genitourinary infections, volume depletion; not antiarrhythmic per se. PubMed

15. Ranolazine (500–1000 mg twice daily; selective cases)
    Purpose: Off-label in ventricular ectopy suppression for some patients.
    Mechanism: Late sodium current inhibition stabilizes repolarization.
    Side effects: Dizziness, drug interactions, QT effects; specialist use. PubMed

16. Dofetilide (requires in-hospital initiation; dose by renal function)
    Purpose: Rarely used for ventricular arrhythmias; more for atrial arrhythmias—mentioned here only because mixed arrhythmia patterns can occur.
    Mechanism: Potassium-channel blockade.
    Side effects: QT prolongation; inpatient monitoring required. PubMed

17. Beta-blocker plus flecainide strategy (specialist-selected)
    Purpose: Reduce VT burden when structural status allows and other options failed.
    Mechanism: Sympathetic blockade plus sodium-channel effect on reentry circuits.
    Side effects: Pro-arrhythmia if used inappropriately; EP oversight essential. PubMed

18. Electrolyte supplementation (K/Mg) when low
    Purpose: Correct documented deficiencies to stabilize rhythm.
    Mechanism: Normalizing membrane currents reduces ectopy/torsades risk.
    Side effects: High K can be dangerous—must be lab-guided. PubMed

19. Short-term beta-blocker up-titration during high-stress periods (clinician-directed)
    Purpose: Temporarily blunt adrenergic surges.
    Mechanism: Decreases catecholamine-driven arrhythmias during acute triggers.
    Side effects: Bradycardia/hypotension. PubMed

20. Antiarrhythmic bridging around ablation/ICD programming changes
    Purpose: Stabilize rhythm during transitions.
    Mechanism: Short-term use of sotalol/amiodarone per EP plan.
    Side effects: As above; close monitoring. European Society of Cardiology

---

Dietary molecular supplement ideas

Important: No supplement has proven disease-modifying benefit for ARVC/ACM. Avoid self-supplementing electrolytes without labs. Consider any supplement only after your cardiologist checks for drug interactions and arrhythmia risk. PubMed

1. Omega-3 from food (or modest supplements if approved)
   Dose/Use: Fatty fish 1–2 times/week; supplements only if clinician agrees.
   Function/Mechanism: Anti-inflammatory, triglyceride-lowering; mixed data for ventricular arrhythmias. Food-first is safest. PubMed

2. Magnesium (only if low on labs)
   Dose: Personalized to deficiency.
   Function: Stabilizes myocardial membranes, reduces ectopy when deficient.
   Mechanism: Affects ion channels and repolarization. PubMed

3. Potassium (dietary emphasis; supplement only if prescribed)
   Dose: Food sources (fruits/vegetables); pills only under supervision.
   Function: Normal K reduces arrhythmia risk; too much is dangerous.
   Mechanism: Sets resting membrane potential. PubMed

4. Coenzyme Q10 (uncertain benefit)
   Dose: Often 100–200 mg/day if used.
   Function: Mitochondrial cofactor; sometimes tried in cardiomyopathy symptoms.
   Mechanism: May support cellular energetics; evidence in ARVC lacking. PubMed

5. Vitamin D (correct deficiency only)
   Dose: Per lab-guided repletion protocol.
   Function: General cardiovascular/immune support when deficient.
   Mechanism: Nuclear receptor signaling; no direct antiarrhythmic proof. PubMed

6. Thiamine (if diuretic-related depletion)
   Dose: Replacement if clinically indicated.
   Function: Supports myocardial energy metabolism.
   Mechanism: Cofactor for oxidative metabolism; deficiency can mimic HF. PubMed

7. Taurine (experimental for arrhythmias; evidence limited)
   Dose: Not standardized.
   Function: Membrane stabilization; data mostly non-ACM.
   Mechanism: Modulates calcium handling; discuss risks/benefits first. PubMed

8. Riboflavin/niacin (only for documented deficiency)
   Dose: Dietary recommended intake or targeted repletion.
   Function: General metabolic support; not antiarrhythmic therapy.
   Mechanism: Redox coenzymes; no ARVC-specific data. PubMed

9. Sodium restriction (nutrition strategy, not a pill)
   Use: ~1.5–2 g/day if heart-failure symptoms—per clinician advice.
   Function: Limits fluid retention in RV failure.
   Mechanism: Lowers neurohormonal stress/volume load. PubMed

10. Mediterranean-pattern eating (whole-diet “supplement”)
    Use: Daily pattern, lifelong.
    Function: Improves overall cardiovascular health and comorbid risks.
    Mechanism: Anti-inflammatory, lipid and BP benefits. PubMed

---

Immunity-booster / regenerative / stem-cell drugs

There are no approved immune-booster, regenerative, or stem-cell drugs that treat the underlying fibrosis/fat replacement in ARVC/ACM. Experimental regenerative or gene-based approaches exist in research settings, but they are not established care and should not be pursued outside clinical trials at expert centers. If you see commercial “stem cell” offers, be cautious—these are not guideline-recommended. The safest path is guideline-based rhythm control, lifestyle measures, and device/procedural therapies when indicated. European Society of Cardiology+1

In rare cases of active myocardial inflammation or overlap with myocarditis, immunosuppressive therapy may be used only when clearly indicated and confirmed by expert evaluation and imaging/biopsy; this is not routine ARVC care. PubMed

---

Surgical/procedural treatments

1. ICD (implantable cardioverter-defibrillator)
   Procedure: A small device is implanted under the skin with leads to the heart to detect and stop life-threatening rhythms.
   Why: It prevents sudden cardiac death in high-risk patients or those with prior sustained VT/VF, per guideline criteria. European Society of Cardiology

2. Catheter ablation (endocardial ± epicardial)
   Procedure: Thin catheters map and burn (“ablate”) arrhythmia circuits; many ARVC circuits are on the heart’s outer surface, so epicardial ablation is often needed.
   Why: To reduce recurrent VT/ICD shocks when medicines are not enough; it can lessen but may not eliminate arrhythmias. European Society of Cardiology

3. Cardiac transplantation
   Procedure: Replace the diseased heart with a donor heart.
   Why: For end-stage biventricular failure or uncontrollable arrhythmias despite maximal therapy, in carefully selected patients. European Society of Cardiology

4. Left cardiac sympathetic denervation (LCSD) — selected cases
   Procedure: Interrupts part of the sympathetic nerve supply to the heart.
   Why: Considered by some centers for refractory ventricular arrhythmias when other options fail; evidence is limited and patient selection is strict. European Society of Cardiology

5. Temporary mechanical support (bridge to decision/transplant)
   Procedure: Devices like ECMO or ventricular assist devices in critical illness.
   Why: Short-term support in severe decompensation while planning definitive therapy. European Society of Cardiology

---

Prevention tips

1. Know your gene/family status and keep relatives informed about testing and surveillance. Heart Rhythm Journal

2. Avoid competitive/high-intensity endurance sports; follow a clinician-approved low-intensity plan. European Society of Cardiology+1

3. Take prescribed medicines exactly as directed; do not stop beta-blockers suddenly. PubMed

4. Keep potassium and magnesium in the normal range; never self-dose without labs. PubMed

5. Limit alcohol and avoid stimulants (energy drinks, illicit drugs, certain decongestants). PubMed

6. Get vaccinated and treat infections promptly to minimize systemic stressors. PubMed

7. Maintain a heart-healthy diet pattern and healthy weight to lower comorbid risk. PubMed

8. Keep a list of “avoid” drugs (QT-prolongers, strong stimulants) and review new meds with your team. PubMed

9. Attend regular specialist follow-ups with ECG/Holter/echo/CMR as advised. European Society of Cardiology

10. Build an emergency plan: family CPR/AED awareness and when to call for help. PubMed

---

When to see a doctor urgently

Seek urgent care if you have sustained palpitations with dizziness, fainting, near-fainting, chest pain, new shortness of breath, or ICD shocks (especially multiple shocks). New swelling of the legs/abdomen, sudden weight gain, or severe fatigue can signal right-sided heart failure and also require prompt review. If a close relative is newly diagnosed with ARVC/ACM or a disease-causing gene, schedule evaluation and, if recommended, genetic testing. European Society of Cardiology

---

What to eat and what to avoid

What to eat: Focus on a Mediterranean-style pattern—vegetables, fruits, legumes, whole grains, nuts, seeds, olive oil, and regular fish—plus adequate but not excessive protein. If you have fluid retention, talk to your clinician about sodium limits (often ~1.5–2 g/day) and daily weights. Keep potassium-rich foods in balance if your labs and medications allow. Hydrate sensibly, especially in hot weather, to avoid arrhythmia-triggering dehydration. PubMed

What to avoid: Ultra-processed foods high in salt, sugar, and trans fats; binge alcohol; energy drinks and stimulant supplements; and unverified “heart boosters” sold online. Do not start electrolyte pills (potassium, magnesium) or herbals with QT effects without medical advice. PubMed

---

Frequently asked questions

1) Is ARVC/ACM the same as ventricular dysplasia?
They refer to the same disease family. “Ventricular dysplasia/ARVC” was the older term; “arrhythmogenic cardiomyopathy (ACM)” is today’s broader name covering right, left, and biventricular forms. Heart Rhythm Journal

2) How is it diagnosed?
Doctors combine ECG, Holter, echocardiogram, cardiac MRI, family/genetic data, and sometimes biopsy. They use structured criteria (2010 Revised Task Force; 2020 Padua criteria) to score major/minor findings. PubMed+1

3) Why is exercise restricted?
High-intensity endurance stress increases arrhythmic events and may speed disease expression in gene carriers; guidelines advise against competitive sports. European Society of Cardiology+1

4) Can medicines cure it?
No medicine reverses scar/fat replacement. Drugs control arrhythmias and treat heart-failure features; devices/procedures address life-threatening rhythms. European Society of Cardiology

5) Who needs an ICD?
People meeting guideline criteria—for example, those who’ve had sustained VT/VF or have high predicted risk—benefit from ICDs to prevent sudden death. Decisions are individualized. European Society of Cardiology

6) Does catheter ablation fix the problem forever?
Ablation can markedly reduce VT and ICD shocks, but scar may evolve, so arrhythmias can recur; it’s often part of a long-term plan with meds/ICD. European Society of Cardiology

7) Should my family be tested?
Yes—first-degree relatives should get clinical screening and often genetic testing if a familial variant is known. Heart Rhythm Journal

8) Are supplements helpful?
No supplement is proven to change ARVC/ACM outcomes. Some (like K/Mg) help only if you’re deficient; always ask your clinician first. PubMed

9) Can I ever exercise?
Yes, but at low intensity under medical guidance. The focus is safety, avoiding competitive and high-intensity endurance activity. European Society of Cardiology

10) What imaging is most useful?
Cardiac MRI is particularly helpful to see scar/fatty replacement and ventricular function; echo and ECG/Holter add key information. European Society of Cardiology

11) What if my ECG and echo are normal but I carry a gene?
You still need periodic follow-up and tailored activity advice; disease can appear later or remain mild. Heart Rhythm Journal

12) Is pregnancy safe?
Many do well with planning and close monitoring; your team will adjust medicines and activity and watch rhythm burden and ventricular function. PubMed

13) Do I need to avoid fevers or dehydration?
Yes—illness, fever, and low fluids can trigger arrhythmias; treat infections promptly and maintain hydration per medical advice. PubMed

14) Which doctors should I see?
An electrophysiologist and a cardiomyopathy/inherited arrhythmia clinic are ideal, coordinating genetics, imaging, and rhythm care. Heart Rhythm Journal

15) Are the criteria changing?
Yes—diagnostic frameworks continue to evolve (e.g., 2024 proposals). Your team applies the latest validated criteria to your case. International Journal of Cardiology

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 23, 2025.